Eric L. Dobmeier
Chief Operating Officer
Eric Dobmeier joined Seattle Genetics in March 2002 and has served as our Chief Operating Officer since June 2011. He oversees the company's business development, corporate communications, manufacturing and program/alliance management groups, as well as corporate strategy initiatives. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the ex-U.S./Canada development and commercialization agreement with Takeda Pharmaceutical Company for ADCETRIS® and ten ADC collaborations with leading biotechnology and pharmaceutical companies. He has also been directly involved in raising more than $1.2 billion in capital for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions.
Mr. Dobmeier serves on the Boards of Directors of Stemline Therapeutics, Inc. and Atara Biotherapeutics, Inc. He holds a J.D. from University of California, Berkeley School of Law and an A.B. in History from Princeton University.